Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CHRFAM7A diversifies human immune adaption through Ca2+ signalling and actin cytoskeleton reorganization.
Szigeti K, Ihnatovych I, Notari E, Dorn RP, Maly I, He M, Birkaya B, Prasad S, Byrne RS, Indurthi DC, Nimmer E, Heo Y, Retfalvi K, Chaves L, Sule N, Hofmann WA, Auerbach A, Wilding G, Bae Y, Reynolds J. Szigeti K, et al. Among authors: sule n. EBioMedicine. 2024 May;103:105093. doi: 10.1016/j.ebiom.2024.105093. Epub 2024 Apr 2. EBioMedicine. 2024. PMID: 38569318 Free PMC article.
Syngeneic model of carcinogen-induced tumor mimics basal/squamous, stromal-rich, and neuroendocrine molecular and immunological features of muscle-invasive bladder cancer.
Shah SD, Gillard BM, Wrobel MM, Karasik E, Moser MT, Mastri M, Long MD, Sule N, Brackett CM, Huss WJ, Foster BA. Shah SD, et al. Among authors: sule n. Front Oncol. 2023 Feb 3;13:1120329. doi: 10.3389/fonc.2023.1120329. eCollection 2023. Front Oncol. 2023. PMID: 36816919 Free PMC article.
The impact of NCCN-compliant multidisciplinary conference on the uptake of active surveillance among eligible patients with localized prostate cancer.
Hussein AA, Shabir U, Mahmood AW, Harrington G, Khan M, Ahmad A, Howlader M, Colan N, Shah AA, Ghadersohi S, Jing Z, Xu B, Sule N, Kauffman E, Kuettel M, Guru K. Hussein AA, et al. Among authors: sule n. Urol Oncol. 2023 Dec;41(12):483.e21-483.e26. doi: 10.1016/j.urolonc.2023.09.013. Epub 2023 Nov 7. Urol Oncol. 2023. PMID: 37945390
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Dimopoulos MA, et al. Among authors: sule n. Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0. Lancet Haematol. 2023. PMID: 37793771 Clinical Trial.
Quantifying face mask comfort.
Koh E, Ambatipudi M, Boone DL, Luehr JBW, Blaise A, Gonzalez J, Sule N, Mooney DJ, He EM. Koh E, et al. Among authors: sule n. J Occup Environ Hyg. 2022 Jan;19(1):23-34. doi: 10.1080/15459624.2021.2002342. Epub 2021 Dec 16. J Occup Environ Hyg. 2022. PMID: 34747682
59 results